Thyroid Medication Recall: Urgent FDA Class I Warning (25 SEP 2026)
Thyroid Medication Recall Escalates to FDA’s Most Serious Warning Level A thyroid medication recall first announced in August has now been upgraded to the FDA’s most urgent risk category. The agency classified Vitruvias Therapeutics’ recall of its 30 mg Thyroid Tablets, USP as a Class I recall on September 22, 2026 — the highest designation […]
